Greenway Greenhouse Cannabis Past Earnings Performance
Past criteria checks 0/6
Greenway Greenhouse Cannabis's earnings have been declining at an average annual rate of -32.3%, while the Pharmaceuticals industry saw earnings growing at 48.2% annually. Revenues have been growing at an average rate of 59% per year.
Key information
-32.3%
Earnings growth rate
-37.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 59.0% |
| Return on equity | -39.6% |
| Net Margin | -90.3% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Greenway Greenhouse Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 5 | -5 | 3 | 0 |
| 31 Dec 23 | 5 | -5 | 3 | 0 |
| 30 Sep 23 | 5 | -4 | 3 | 0 |
| 30 Jun 23 | 5 | -4 | 3 | 0 |
| 31 Mar 23 | 6 | -3 | 3 | 0 |
| 31 Dec 22 | 5 | -3 | 3 | 0 |
| 30 Sep 22 | 4 | -2 | 3 | 0 |
| 30 Jun 22 | 4 | -3 | 3 | 0 |
| 31 Mar 22 | 2 | -3 | 2 | 0 |
| 31 Dec 21 | 2 | -2 | 2 | 0 |
| 30 Sep 21 | 1 | -2 | 1 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
Quality Earnings: GWAY is currently unprofitable.
Growing Profit Margin: GWAY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GWAY is unprofitable, and losses have increased over the past 5 years at a rate of 32.3% per year.
Accelerating Growth: Unable to compare GWAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GWAY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-40.8%).
Return on Equity
High ROE: GWAY has a negative Return on Equity (-39.64%), as it is currently unprofitable.